Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619391 · ClinicalTrials.gov registry record · NA
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT07619391: Recruiting NA study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT07619391 is a NA study that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07619391, a NA study, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer. Pancreatic cancer is best treated with many care teams, such as medical oncology and surgery, requiring patients to dedicate significant time coordinating appointments among different doctors. This time commitment is referred to as time toxicity, defined as the time spent undergoing cancer-related medical care, such as emergency visits, ambulatory care, lab and infusion visits, hospitalizations, and the commuting and waiting times associated with each. At present, time toxicity is still understudied within the medical literature, with no gold standard established for the method of measurement. The MyCap mobile app may be a feasible way to track the time burden from treatment for patients with pancreatic cancer.
Primary Outcome
Defined as the number of participants who enroll in the study and complete at least one time log during the study period.
Interventions
- OTHER Survey Administration
- OTHER Electronic Health Record Review
- BEHAVIORAL Smartphone Application-based Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-10 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT07619391 shows while recruiting
NCT07619391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Survey Administration is the first listed.
NCT07619391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07619391 about?
NCT07619391 is a clinical study titled "MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer". This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer. Pancreatic cancer is best treated with many care teams, such as medical oncology and surgery, requiring patients to dedicate significant ...
What is the current status of trial NCT07619391?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-03-10. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07619391?
The interventions under investigation include: Survey Administration (OTHER), Electronic Health Record Review (OTHER), Smartphone Application-based Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT07619391?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07619391's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI